Press Releases InMed Pharmaceuticals Inc.

Equities

INM

CA4576376012

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
0.23 ^USD	-8.73%		-20.72%	-44.71%

Apr. 18	InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board	CI
Apr. 04	InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board	Apr. 18	NE
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration	Apr. 16	NE
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies	Apr. 04	NE
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance	Mar. 20	NE
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update	Feb. 13	NE
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer	Feb. 09	NE
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET	Jan. 18	NE
InMed Pharmaceuticals Provides Business Update and Milestones for 2024	Jan. 16	NE
InMed Announces Results of 2023 Annual General Meeting	Dec. 19	NE
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration	Nov. 29	NE
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update	Nov. 14	NE
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023	Nov. 02	NE
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules	23-10-26	NE
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules	23-10-24	NE
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies	23-10-24	NE
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update	23-09-29	NE
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-26	AQ
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance	23-09-22	NE
INMED PHARMACEUTICALS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-06-01	AQ
INMED PHARMACEUTICALS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-05-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases InMed Pharmaceuticals Inc.

Equities

INM

CA4576376012

Press Releases

Filters